F. Cvitkovic

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7

The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

Targeted glycan degradation potentiates the anticancer immune response in vivo

Shortening of 3′UTRs Correlates with Poor Prognosis in Breast and Lung Cancer

Cancer immunotherapy: the beginning of the end of cancer?

Cancer treatment and survivorship statistics, 2022

Determining cell type abundance and expression from bulk tissues with digital cytometry

Elements of cancer immunity and the cancer–immune set point

Combination cancer immunotherapy and new immunomodulatory targets

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Exercise Standards for Testing and Training

The multilayered complexity of ceRNA crosstalk and competition

Chemoimmunotherapy: reengineering tumor immunity

Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity

Delivery technologies for cancer immunotherapy

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

Tumeurs stromales digestives : rôle de la tomodensitométrie avant et après traitement

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

Myocarditis

Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal

Next generation of immune checkpoint therapy in cancer: new developments and challenges

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Molecular mechanisms of T cell co-stimulation and co-inhibition

Emerging Biological Principles of Metastasis

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

Immunotherapy for Breast Cancer: Current and Future Strategies

The blockade of immune checkpoints in cancer immunotherapy

LAG-3 in Cancer Immunotherapy

Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer

IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza

Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable

Cisplatin in cancer therapy: Molecular mechanisms of action

Clonal evolution in cancer

The CD4-like molecule LAG-3, biology and therapeutic applications

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

The PI3K Pathway in Human Disease

Metastatic colonization by circulating tumour cells

Molecular and cellular insights into T cell exhaustion

Interferons as potential adjuvants in prophylactic vaccines

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Cancer Chemotherapy and Cardiac Arrhythmias: A Review

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Myocarditis

Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society

Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer

Magnesium in Man: Implications for Health and Disease

Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions

Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

Nanotechnology for Multimodal Synergistic Cancer Therapy

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Immune targeting in breast cancer.

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Cancer treatment and survivorship statistics, 2016

The future of immune checkpoint therapy

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

Immune‐Related Adverse Events From Immune Checkpoint Inhibitors

Cancer treatment and survivorship statistics, 2019

Monitoring of Anthracycline-Induced Cardiotoxicity

Reactive Oxygen Species (ROS)-Based Nanomedicine

Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Cardiovascular Complications of Cancer Therapy

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study

Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.

[Gastrointestinal stromal tumors].